Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
PHASE-II TRIAL OF NITROGEN-MUSTARD, VINCRISTINE, AND PROCARBAZINE IN PATIENTS WITH RECURRENT GLIOMA - NORTH CENTRAL CANCER-TREATMENT GROUP RESULTS
Autore:
GALANIS E; BUCKNER JC; BURCH PA; SCHAEFER PL; DINAPOLI RP; NOVOTNY PJ; SCHEITHAUER BW; ROWLAND KM; VUKOV AM; MAILLIARD JA; MORTON RF;
Indirizzi:
MAYO CLIN & MAYO FDN,200 1ST ST SW ROCHESTER MN 55905 MAYO CLIN & MAYO FDN ROCHESTER MN 55905 TOLEDO COMMUNITY HOSP,COMMUNITY CLIN ONCOL PROGRAM TOLEDO OH 43601 CARLE CANC CTR,COMMUNITY CLIN ONCOL PROGRAM URBANA IL 61801 ILLINOIS ONCOL RES ASSOC,COMMUNITY CLIN ONCOL PROGRAM PEORIA IL 61601 UNIV NEBRASKA,MED CTR,CREIGHTON UNIV,NEBRASKA ONCOL GRP OMAHA NE 68108 IOWA ONCOL RES ASSOC,COMMUNITY CLIN ONCOL PROGRAM DES MOINES IA 50318
Titolo Testata:
Journal of clinical oncology
fascicolo: 9, volume: 16, anno: 1998,
pagine: 2953 - 2958
SICI:
0732-183X(1998)16:9<2953:PTONVA>2.0.ZU;2-7
Fonte:
ISI
Lingua:
ENG
Soggetto:
PRIMARY BRAIN-TUMORS; COMBINATION CHEMOTHERAPY; MALIGNANT GLIOMAS; CHILDREN; OLIGODENDROGLIOMA; THERAPY; ADULTS; MOPP; CCNU; AZQ;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
26
Recensione:
Indirizzi per estratti:
Citazione:
E. Galanis et al., "PHASE-II TRIAL OF NITROGEN-MUSTARD, VINCRISTINE, AND PROCARBAZINE IN PATIENTS WITH RECURRENT GLIOMA - NORTH CENTRAL CANCER-TREATMENT GROUP RESULTS", Journal of clinical oncology, 16(9), 1998, pp. 2953-2958

Abstract

Purpose: Previous investigators have reported responses in 52% of patients treated with mechlorethamine (nitrogen mustard), vincristine, and procarbazine (MOP) for recurrent glioma. To confirm these promising results, we conducted a phase II prospective study. Patients and Methods: Sixty-three patients with histologic confirmation of recurrent glioma were treated with the MOP regimen, Patients with or without prior chemotherapy received nitrogen mustard 3 mg/m(2) or 6 mg/m(2), respectively, intravenously on days 1 and 8 plus vincristine 2 mg/m(2) intravenously on days 1 and 8, and procarbazine 100 mg/m(2) orally on days 1to 14. Cycles were repeated every 28 days, Results: Of 61 patients assessable for response, eight responded (13%), with one complete response (CR), Responses were as follows: low-grade gliomas, 19%; anaplasticastrocytomas, 11%; anaplastic oligodendrogliomas or oligoastrocytomas, 25%; and glioblastomas, 4.3%, The most common toxicity was myelosuppression with leukocyte nadirs less than 1,000/mu L in 23% and plateletnadirs less than 25,000/mu L in 13% of patients. Two patients died ofinfection in the setting of neutropenia, Nonhematologic toxicity included neurosensory changes in 21% of patients (severe in 3%) and severedermatologic reactions in 8%. In multivariate analysis, Eastern Cooperative Oncology group (ECOG) performance status (PS) was the best predictor for response to chemotherapy (P = .01) and time to progression (P = .008), while PS and grade were the most important predictors of survival (P = .002 and .05, respectively). Conclusion: This study did not confirm the high response rate previously reported in recurrent gliomas. Patients with recurrent anaplastic oligodendrogliomas or oligoastrocytomas and recurrent low-grade gliomas had the highest response rates (25% and 19%, respectively), In multivariate analysis, ECOG PS was the best predictor of response, while PS and tumor grade were the mostimportant predictors of survival. J Clin Oncol 16:2953-2958. (C) 1998by American Society of Clinical Oncology.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 02/12/20 alle ore 05:22:20